Precision BioSciences, Inc. (NASDAQ:DTIL) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Precision BioSciences, Inc. (NASDAQ:DTIL) have received a consensus recommendation of “Moderate Buy” from the five brokerages that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $32.25.

DTIL has been the subject of several research analyst reports. Jefferies Financial Group reaffirmed a “buy” rating and issued a $19.00 price target on shares of Precision BioSciences in a research note on Friday, March 13th. Wall Street Zen raised shares of Precision BioSciences from a “sell” rating to a “hold” rating in a research report on Saturday, March 14th. Weiss Ratings upgraded Precision BioSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 8th. Oppenheimer assumed coverage on Precision BioSciences in a research report on Tuesday, June 9th. They issued an “outperform” rating and a $20.00 target price for the company. Finally, HC Wainwright reaffirmed a “buy” rating and set a $60.00 price target on shares of Precision BioSciences in a research note on Wednesday, May 27th.

Precision BioSciences Stock Performance

Shares of DTIL stock opened at $8.18 on Friday. The firm has a 50 day moving average of $7.13 and a 200-day moving average of $5.71. The company has a market cap of $211.04 million, a price-to-earnings ratio of -2.23 and a beta of 1.25. The company has a quick ratio of 14.02, a current ratio of 14.02 and a debt-to-equity ratio of 0.29. Precision BioSciences has a 52 week low of $3.53 and a 52 week high of $8.82.

Precision BioSciences (NASDAQ:DTIL) last released its earnings results on Tuesday, May 5th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.09). The company had revenue of $10.84 million for the quarter, compared to analyst estimates of $4.05 million. Precision BioSciences had a negative net margin of 96.73% and a negative return on equity of 85.37%. On average, equities analysts forecast that Precision BioSciences will post -2.21 earnings per share for the current year.

Hedge Funds Weigh In On Precision BioSciences

Institutional investors have recently modified their holdings of the company. HBK Sorce Advisory LLC bought a new position in shares of Precision BioSciences in the 4th quarter worth $38,000. Engineers Gate Manager LP bought a new stake in Precision BioSciences during the 4th quarter valued at $43,000. Occudo Quantitative Strategies LP bought a new stake in Precision BioSciences during the 4th quarter valued at $52,000. Miller Financial Services LLC raised its holdings in Precision BioSciences by 50.0% during the fourth quarter. Miller Financial Services LLC now owns 15,000 shares of the company’s stock worth $62,000 after buying an additional 5,000 shares during the last quarter. Finally, Virtu Financial LLC acquired a new position in Precision BioSciences during the third quarter worth $84,000. 37.99% of the stock is owned by institutional investors and hedge funds.

Precision BioSciences Company Profile

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.